Abstract
Jun dimerization protein 2 (JDP2) forms a dimeric complex that can include members of the Jun, Fos, ATF-2, Maf and other families of AP-1 proteins. JDP2 acts as a repressor that binds to the AP-1 site in promoters and is a possible tumor-suppressor. We describe here how the transactivation of the c-Jun gene by p300 and ATF-2 involves recruitment of the histone deacetylase complex (HDAC3), with repression of retinoic acid-induced (RA-induced) transcription of the c- Jun gene and subsequent inhibition of the RA-mediated differentiation of F9 cells. We summarize that JDP2 has activities associated with histone binding and inhibition of histone acetyltransferases (INHAT), as well as with the regulation of chromatin assembly. These observations indicate that JDP2 not only acts as a sequence-specific DNA-binding protein but also controls the transcription of AP-1-responsive genes by direct regulation of histone modification. We discuss here a new perspective on the role of JDP2 in the chromatin-related mechanism that regulates the transcription of genes that are the targets of AP-1 proteins.
Keywords: histone acetyltransferases, ap proteins, dna-binding protein, cyclic amp response element, oncogenic, tumorigenesis, chip assays, transformation
Current Genomics
Title: Jun Dimerization Protein 2: A Multifunctional Transcription Factor in Mammalian Cells
Volume: 6 Issue: 5
Author(s): T. Yamasaki, M. Noguchi, B. Liu, K. Nakade, P- C. Wang, T. Murata and K. K. Yokoyama
Affiliation:
Keywords: histone acetyltransferases, ap proteins, dna-binding protein, cyclic amp response element, oncogenic, tumorigenesis, chip assays, transformation
Abstract: Jun dimerization protein 2 (JDP2) forms a dimeric complex that can include members of the Jun, Fos, ATF-2, Maf and other families of AP-1 proteins. JDP2 acts as a repressor that binds to the AP-1 site in promoters and is a possible tumor-suppressor. We describe here how the transactivation of the c-Jun gene by p300 and ATF-2 involves recruitment of the histone deacetylase complex (HDAC3), with repression of retinoic acid-induced (RA-induced) transcription of the c- Jun gene and subsequent inhibition of the RA-mediated differentiation of F9 cells. We summarize that JDP2 has activities associated with histone binding and inhibition of histone acetyltransferases (INHAT), as well as with the regulation of chromatin assembly. These observations indicate that JDP2 not only acts as a sequence-specific DNA-binding protein but also controls the transcription of AP-1-responsive genes by direct regulation of histone modification. We discuss here a new perspective on the role of JDP2 in the chromatin-related mechanism that regulates the transcription of genes that are the targets of AP-1 proteins.
Export Options
About this article
Cite this article as:
Yamasaki T., Noguchi M., Liu B., Nakade K., Wang C. P-, Murata T. and Yokoyama K. K., Jun Dimerization Protein 2: A Multifunctional Transcription Factor in Mammalian Cells, Current Genomics 2005; 6 (5) . https://dx.doi.org/10.2174/1389202054750194
DOI https://dx.doi.org/10.2174/1389202054750194 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions
Current Medicinal Chemistry Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Preclinical Evidence on the Anticancer Properties of Food Peptides
Protein & Peptide Letters The Role of Parthenolide in Intracellular Signalling Processes: Review of Current Knowledge
Current Signal Transduction Therapy The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Apoptosis and Acute Brain Ischemia in Ischemic Stroke
Current Vascular Pharmacology Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects
Current Pharmaceutical Design P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry Combined Anticancer Therapies: An Overview of the Latest Applications
Anti-Cancer Agents in Medicinal Chemistry Advances in Hydrogels Applied to Degenerative Diseases
Current Pharmaceutical Design In Vitro Inhibitory Effect of Recombinant Human Calprotectin on Nalm6 Leukemia Cell Line
Anti-Cancer Agents in Medicinal Chemistry Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets Hydrogels: A Journey from Diapers to Gene Delivery
Mini-Reviews in Medicinal Chemistry Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry A Therapeutic Potential of Animal β-hairpin Antimicrobial Peptides
Current Medicinal Chemistry Inhibition of Cdc42-Interacting Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression
Current Cancer Drug Targets